Lantheus Holdings, Inc. (LNTH): Price and Financial Metrics


Lantheus Holdings, Inc. (LNTH)

Today's Latest Price: $15.96 USD

0.56 (3.64%)

Updated Jan 22 6:55pm

Add LNTH to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 64 in Medical - Diagnostics/Research

See all "A" rated Strong Buy stocks

LNTH Stock Summary

  • With a price/earnings ratio of 2,743.62, Lantheus Holdings Inc P/E ratio is greater than that of about 99.58% of stocks in our set with positive earnings.
  • The price/operating cash flow metric for Lantheus Holdings Inc is higher than 82.33% of stocks in our set with a positive cash flow.
  • The volatility of Lantheus Holdings Inc's share price is greater than that of merely 14.44% US stocks with at least 200 days of trading history.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Lantheus Holdings Inc are MSTR, CYBR, HQY, JVA, and SGH.
  • LNTH's SEC filings can be seen here. And to visit Lantheus Holdings Inc's official web site, go to www.lantheus.com.

LNTH Stock Price Chart Interactive Chart >

Price chart for LNTH

LNTH Price/Volume Stats

Current price $15.96 52-week high $19.20
Prev. close $15.40 52-week low $8.67
Day low $15.27 Volume 526,600
Day high $16.00 Avg. volume 504,893
50-day MA $14.01 Dividend yield N/A
200-day MA $13.52 Market Cap 1.07B

Lantheus Holdings, Inc. (LNTH) Company Bio


Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic medical imaging agents and products for the diagnosis and treatment of cardiovascular and other diseases worldwide. The company was founded in 1956 and is based in North Billerica, Massachusetts.

LNTH Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$15.96$6.17 -61%

The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Lantheus Holdings Inc. To summarize, we found that Lantheus Holdings Inc ranked in the 30th percentile in terms of potential gain offered. Our DCF analysis suggests the stock is overvalued by about 61.17%. In terms of the factors that were most noteworthy in this DCF analysis for LNTH, they are:

  • Lantheus Holdings Inc's effective tax rate, as measured by taxes paid relative to net income, is at 163 -- greater than 98.59% of US stocks with positive free cash flow.
  • The weighted average cost of capital for the company is 11. This value is greater than 83.88% stocks in the Healthcare sector that generate free cash flow.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%-62%
1%-62%
2%-61%
3%-61%
4%-61%
5%-60%

For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as LNTH, try HOLX, ICLR, HAPP, JNJ, and VIVO.


LNTH Latest News Stream


Event/Time News Detail
Loading, please wait...

LNTH Latest Social Stream


Loading social stream, please wait...

View Full LNTH Social Stream

Latest LNTH News From Around the Web

Below are the latest news stories about Lantheus Holdings Inc that investors may wish to consider to help them evaluate LNTH as an investment opportunity.

Lantheus files U.S. application for PD-L1 imaging biomarker

Lantheus ([[LNTH]] +4.0%) has filed a Drug Master File with the FDA for NM-01, a PD-L1 imaging biomarker, and will begin making the biomarker available to academic centers and pharmaceutical companies for use in immuno-oncology trials in 2021.NM-01 is a proprietary radiopharmaceutical biomarker using a camelid single-domain antibody and a technetium-99...

Seeking Alpha | January 12, 2021

Lantheus Holdings Announces Submission of Drug Master File for NM-01 in the U.S.

NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus), the parent company of Lantheus Medical Imaging, Inc. and Progenics Pharmaceuticals, Inc., and a global leader in the development, manufacture and commercialization of innovative diagnostic and therapeutic agents and products, announced that it has filed a Drug Master File (DMF) with the U.S. Food and Drug Administration (FDA) for NM-01, a PD-L1 imaging biomarker, and will begin making the biomarker avail

Business Wire | January 12, 2021

Is LNTH A Good Stock To Buy Now?

Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our investment process because our research has shown that the elite investors’ consensus returns have been exceptional. In the following paragraphs, we find out […]

Yahoo | December 15, 2020

Nuclear Medicine Market Booming Worldwide Opportunity, Upcoming Trends and Growth Forecast 2030 |orthStar Medical Radioisotopes LLC, Progenics Pharmaceuticals Inc., Bracco S.p.A., Curium Pharma, Life Molecular Imaging, Bayer AG, Lantheus Holdings Inc

The Nuclear Medicine/Radiopharmaceuticals Market was worth US$ 6.5 Billion in 2019 and is expected to grow at a CAGR of 8.9% through 2030. The major factor driving the growth of global market is the increasing prevalence of cancer patients across

OpenPR | December 11, 2020

PyL™ (18F-DCFPyL), Lantheus’ PSMA-Targeted Prostate Cancer Imaging Agent, to be Used in POINT Biopharma’s PSMA-Targeted Radioligand Therapeutic Phase 3 Trial in Patients with Metastatic Castration Resistant Prostate Cancer

NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus), the parent company of Lantheus Medical Imaging, Inc. and Progenics Pharmaceuticals, Inc., a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products, today announced it has entered into a strategic collaboration with POINT Biopharma, Inc. (POINT) to use Lantheus’ investigational prostate-specific membrane antigen (PSMA)-targeted positron emi

Business Wire | December 9, 2020

Read More 'LNTH' Stories Here

LNTH Price Returns

1-mo N/A
3-mo 33.33%
6-mo 1.59%
1-year -11.48%
3-year -32.37%
5-year 628.77%
YTD 18.31%
2020 -34.23%
2019 31.05%
2018 -23.47%
2017 137.79%
2016 154.44%

Continue Researching LNTH

Here are a few links from around the web to help you further your research on Lantheus Holdings Inc's stock as an investment opportunity:

Lantheus Holdings Inc (LNTH) Stock Price | Nasdaq
Lantheus Holdings Inc (LNTH) Stock Quote, History and News - Yahoo Finance
Lantheus Holdings Inc (LNTH) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.9203 seconds.